Literature DB >> 18410920

Arginine homeostasis in allergic asthma.

Harm Maarsingh1, Johan Zaagsma, Herman Meurs.   

Abstract

Allergic asthma is a chronic disease characterized by early and late asthmatic reactions, airway hyperresponsiveness, airway inflammation and airway remodelling. Changes in l-arginine homeostasis may contribute to all these features of asthma by decreased nitric oxide (NO) production and increased formation of peroxynitrite, polyamines and l-proline. Intracellular l-arginine levels are regulated by at least three distinct mechanisms: (i) cellular uptake by cationic amino acid (CAT) transporters, (ii) metabolism by NO-synthase (NOS) and arginase, and (iii) recycling from l-citrulline. Ex vivo studies using animal models of allergic asthma have indicated that attenuated l-arginine bioavailability to NOS causes deficiency of bronchodilating NO and increased production of procontractile peroxynitrite, which importantly contribute to allergen-induced airway hyperresponsiveness after the early and late asthmatic reaction, respectively. Decreased cellular uptake of l-arginine, due to (eosinophil-derived) polycations inhibiting CATs, as well as increased consumption by increased arginase activity are major causes of substrate limitation to NOS. Increasing substrate availability to NOS by administration of l-arginine, l-citrulline, the polycation scavenger heparin, or an arginase inhibitor alleviates allergen-induced airway hyperresponsiveness by restoring the production of bronchodilating NO. In addition, reduced l-arginine levels may contribute to the airway inflammation associated with the development of airway hyperresponsiveness, which similarly may involve decreased NO synthesis and increased peroxynitrite formation. Increased arginase activity could also contribute to airway remodelling and persistent airway hyperresponsiveness in chronic asthma via increased synthesis of l-ornithine, the precursor of polyamines and l-proline. Drugs that increase the bioavailability of l-arginine in the airways - particularly arginase inhibitors - may have therapeutic potential in allergic asthma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18410920     DOI: 10.1016/j.ejphar.2008.02.096

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  20 in total

1.  Airway hyperresponsiveness in children with sickle cell anemia.

Authors:  Joshua J Field; Janet Stocks; Fenella J Kirkham; Carol L Rosen; Dennis J Dietzen; Trisha Semon; Jane Kirkby; Pamela Bates; Sinziana Seicean; Michael R DeBaun; Susan Redline; Robert C Strunk
Journal:  Chest       Date:  2010-08-19       Impact factor: 9.410

2.  Arginine cools the inflamed gut.

Authors:  Jörg H Fritz
Journal:  Infect Immun       Date:  2013-07-29       Impact factor: 3.441

3.  Arginase I levels are decreased in the plasma of pediatric patients with atopic dermatitis.

Authors:  Victoria Dimitriades; Paulo C Rodriguez; Jovanny Zabaleta; Augusto C Ochoa
Journal:  Ann Allergy Asthma Immunol       Date:  2014-07-11       Impact factor: 6.347

4.  Binding of α,α-disubstituted amino acids to arginase suggests new avenues for inhibitor design.

Authors:  Monica Ilies; Luigi Di Costanzo; Daniel P Dowling; Katherine J Thorn; David W Christianson
Journal:  J Med Chem       Date:  2011-07-18       Impact factor: 7.446

5.  Role of arginase 1 from myeloid cells in th2-dominated lung inflammation.

Authors:  Luke Barron; Amber M Smith; Karim C El Kasmi; Joseph E Qualls; Xiaozhu Huang; Allen Cheever; Lee A Borthwick; Mark S Wilson; Peter J Murray; Thomas A Wynn
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

6.  Regulation of arginine acquisition and virulence gene expression in the human pathogen Streptococcus pneumoniae by transcription regulators ArgR1 and AhrC.

Authors:  Tomas G Kloosterman; Oscar P Kuipers
Journal:  J Biol Chem       Date:  2011-11-14       Impact factor: 5.157

7.  Modeling gas phase nitric oxide release in lung epithelial cells.

Authors:  Jingjing Jiang; Steven C George
Journal:  Nitric Oxide       Date:  2011-04-30       Impact factor: 4.427

8.  Inhibition of arginase activity enhances inflammation in mice with allergic airway disease, in association with increases in protein S-nitrosylation and tyrosine nitration.

Authors:  Karina Ckless; Anniek Lampert; Jessica Reiss; David Kasahara; Matthew E Poynter; Charles G Irvin; Lennart K A Lundblad; Ryan Norton; Albert van der Vliet; Yvonne M W Janssen-Heininger
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

Review 9.  Arginase: a key enzyme in the pathophysiology of allergic asthma opening novel therapeutic perspectives.

Authors:  Harm Maarsingh; Johan Zaagsma; Herman Meurs
Journal:  Br J Pharmacol       Date:  2009-08-24       Impact factor: 8.739

10.  ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts.

Authors:  Augusto A Litonjua; Jessica Lasky-Su; Kady Schneiter; Kelan G Tantisira; Ross Lazarus; Barbara Klanderman; John J Lima; Charles G Irvin; Stephen P Peters; John P Hanrahan; Stephen B Liggett; Gregory A Hawkins; Deborah A Meyers; Eugene R Bleecker; Christoph Lange; Scott T Weiss
Journal:  Am J Respir Crit Care Med       Date:  2008-07-10       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.